Development of Echinocandin Resistance in *Clavispora lusitaniae* during Caspofungin Treatment[†]

Marie Desnos-Ollivier,^{1,2} Olivier Moquet,³ Taieb Chouaki,⁴
Anne-Marie Guérin,⁵ and Françoise Dromer^{1,2*}

Institut Pasteur, National Reference Center for Mycoses and Antifungals (NRCMA), Molecular Mycology Unit, Paris,¹
CNRS URA3012, Paris,² Laboratoire de Biologie Médicale, Centre Hospitalier de Beauvais, Beauvais,³ Laboratoire de
Parasitologie-Mycologie, Centre Hospitalier Universitaire d'Amiens, Amiens,⁴ and Service de
Réanimation Polyvalente, Centre Hospitalier de Beauvais, Beauvais,⁵ France

Received 15 February 2011/Returned for modification 21 March 2011/Accepted 4 April 2011

***Clavispora lusitaniae* is an opportunistic human pathogen responsible for 0.6 to 2% of candidemia. This species is intrinsically susceptible to echinocandins. Nevertheless, in this study, development of echinocandin resistance in *C. lusitaniae* isolates was observed during caspofungin treatment. This resistance resulted from missense mutation in the echinocandin target *Fks1* gene.**

Candida albicans remains the most common pathogen responsible for invasive candidiasis. However, increasing rates of candidemia caused by other species, including *Clavispora lusitaniae*, are reported worldwide (13, 23). *Clavispora lusitaniae* (anamorph: *Candida lusitaniae*) is an opportunistic haploid ascomycetous yeast (12, 25), recovered worldwide from plants, animals, and humans (4). This species is able to grow at 37°C and accounts for 0.6 to 2% of the isolates recovered during candidemia (12, 18, 23). Caspofungin, a member of the echinocandin class, demonstrates fungicidal activity against *C. albicans*, *Candida tropicalis*, *Candida parapsilosis*, *Candida krusei*, *Candida glabrata*, and *C. lusitaniae*. Beta-1,3-glucan synthase encoded by *Fks* genes is the target of the echinocandins (1, 5). Missense mutations in the hot spot 1 (HS1) and/or HS2 regions, resulting in increased MICs of echinocandins, had already been described in clinical isolates of *C. albicans*, *C. glabrata*, *C. tropicalis*, and *C. krusei* from patients treated with caspofungin (2, 3, 7, 11, 14, 15, 20, 21). *Clavispora lusitaniae* is known for its propensity to develop amphotericin B resistance during therapy (9). It is not intrinsically resistant to echinocandins, and modal caspofungin MIC was 0.25 µg/ml and 0.06 µg/ml (22) (NRCMA, unpublished data). Caspofungin can be used as first-line therapy for candidemia due to *C. lusitaniae* and is even recommended for patients preexposed to azoles. Here, we report the first case of clinical isolates of *C. lusitaniae* with high echinocandin MICs recovered from a patient treated with caspofungin associated with a missense mutation localized in the HS1 region of hypothetical beta-1,3-glucan synthase.

A 77-year-old man was admitted to the intensive care unit after coloanal anastomosis and total cystectomy with bilateral nephrostomy for advanced rectal cancer. On day 7 after admission, the patient developed fever, dyspnea, and polypnea associated with hyperleukocytosis (16.5×10^9 cells/liter, 90%

neutrophils) and increased levels of C-reactive protein (CRP; 184 mg/liter). Culture of both bronchoalveolar lavage (BAL) fluid and urine yielded *C. lusitaniae*. Therapy with cefotaxime (3 g/day) and caspofungin (70 mg on the first day and then 50 mg/day) was started. The patient clinically improved over the next 3 days concurrently with urine and BAL fluid cultures turning negative. Cefotaxime was stopped. On day 16, the patient developed fever, abdominal pain, and dyspnea with biological signs of sepsis (leukocytes at 28×10^9 cells/liter with 85% neutrophils, CRP = 214 mg/liter). Clinical and radiologic findings suggested anastomotic stenosis, and the patient underwent surgical revision. Cultures of urine, perianastomotic tissues, and fluid samples were positive for *C. lusitaniae*, while blood and BAL fluid cultures were sterile. Fluconazole (800 mg on the first day and then 400 mg/day) was added. Urine and abdominal fluid cultures became sterile 3 days after, and clinical condition improved slightly. On day 24, a second surgical revision was performed because of perianastomotic tissue necrosis. Therapy with piperacillin-tazobactam (16 g/day) was started. *C. lusitaniae* was recovered from intra-abdominal fluid, but blood, urine, and BAL fluid cultures were negative. The patient's clinical condition worsened over the next few days. A multidrug-resistant *Acinetobacter baumannii* strain was isolated from blood cultures 5 days after the third surgery. The patient eventually died 29 days after admission.

All fungal isolates were identified by carbon assimilation patterns (ID32C; bioMérieux, Marcy-l'Etoile, France; code 51573701). Identification was confirmed by sequencing of internal transcribed spacer (ITS) and D1/D2 regions using universal primers V9D/LS266 (6, 17) and NL1/NL4 (19), respectively. Clinical isolates had 99% and 100% similarity compared to D1/D2 and ITS sequences, respectively, of the type strain *C. lusitaniae* CBS 4413 (sequence of 323 bp, GenBank AJ508571, and sequence of 310 bp, GenBank AF172262). *In vitro* susceptibility was determined for caspofungin, micafungin, and anidulafungin by a microdilution technique according to the procedure proposed by the Antifungal Susceptibility Testing Subcommittee of EUCAST (AFST-EUCAST [27]), modified by using AM3 medium for caspofungin and micafungin (7). Decreased susceptibility to caspofungin was defined by a MIC

* Corresponding author. Mailing address: Centre National de Référence Mycologie et Antifongiques, Unité de Mycologie Moléculaire, Institut Pasteur, CNRS URA 3012, 25 rue du Docteur Roux, 75724 Cedex 15, Paris, France. Phone: 33(0) 1 40 61 33 89. Fax: 33(0) 1 45 68 84 20. E-mail: dromer@pasteur.fr.

[†] Published ahead of print on 13 April 2011.

TABLE 1. Echinocandin susceptibility and HS1 protein sequence for the 4 clinical isolates of *C. lusitaniae* and type strain CBS 4413

Strain/isolate	Time after caspofungin initiation (days)	Site of isolation	MIC ($\mu\text{g/ml}$)			HS1 protein sequence ^a
			Caspofungin	Micafungin	Anidulafungin	
CBS4413 ^T			0.06	0.03	0.06	FFLTLSLRD
10BL1-59	0	Urine	0.06	0.06	0.06	FFLTLSLRD
10BL1-61	2	BAL fluid	0.125	0.06	0.06	FFLTLSLRD
10BL1-60	11	Urine	4	0.5	1	FFLTLFLRD
10BL1-62	17	Peritoneal fluid	4	4	2	FFLTLFLRD

^a Boldface indicates the mutated residue.

of ≥ 0.5 $\mu\text{g/ml}$ according to previous data showing that clinical isolates of *Candida* spp. exhibiting MICs above these thresholds harbored mutations in target genes (7, 8). Isolates recovered initially from urine (10BL1-59) and BAL fluid (10BL1-61) had low caspofungin MICs, whereas isolates recovered later from urine (10BL1-60) and peritoneal fluid (10BL1-62) had high MICs (Table 1). Of note, Pfaller et al. recently defined epidemiological cutoff values for *C. lusitaniae* for caspofungin, anidulafungin, and micafungin MICs using the CLSI (Clinical and Laboratory Standards Institute) reference method (0.5 $\mu\text{g/ml}$, 2 $\mu\text{g/ml}$, and 0.5 $\mu\text{g/ml}$, respectively) (22).

We then looked for a mutation within the putative *FKS1* gene to help explain the high MIC values. In the genome of *C. lusitaniae* (ATCC 42720) currently annotated in the *Candida* database on the Broad Institute website (http://www.broadinstitute.org/annotation/genome/candida_lusitaniae/MultiHome.html), one hypothetical beta-1,3-glucan synthase protein of 688 amino acids (CLUG_01702 transcript 1, supercontig 2: 965796-967862+) had 83% similarity with the HS2 region of *C. albicans* Fks1p. The DNA sequence localized upstream from this sequence (supercontig 2: 964000-967862+) was compared with the nucleotide sequence of the coding region of the *C. albicans* Fks1 gene (orf19-2929, GenBank D88815.1) and had 79% similarity. Resulting protein sequences of *C. lusitaniae* and *C. albicans* (GenBank BAA21535.1) were compared, and 83% similarity was observed for the 867-amino-acid sequence. For *C. lusitaniae*, protein regions (FFLTLSLRD and WIRRYTSLIF) similar to HS1 and HS2 regions of *C. albicans* (FFSTLSLRD and WIRRYTSLIF, respectively) were localized. Primers were designed to amplify these hypothetical HS1 and HS2 regions of *C. lusitaniae* (Table 2). The sequences were translated with the standard genetic code (<http://bioinformatics.org/sms/index.html>), and resulting protein sequences were compared (BioMics, v7.2.5; BioAware SA, Hannut, Belgium). Numbering of the protein sequence was based on *C. albicans* Fks1p. The initial isolates (10BL1-59 and 10BL1-61, GenBank JF304615) showed a protein sequence for

the HS1 region identical to that of ATCC 42720 and CBS 4413 and were considered wild type. The subsequent isolates shared similar nucleotide sequences (GenBank JF304613), leading to a missense mutation, S645F, localized in the HS1 region (Table 1). The 4 isolates had a wild-type protein sequence for the HS2 region (GenBank JF304614).

Development of antifungal resistance has been described for yeasts and filamentous fungi after environmental exposure or clinical treatment (15, 21, 26, 28). Although specific data on caspofungin are lacking, antimicrobial drug distribution has been shown to be potentially impaired in critically ill patients. This could have resulted in subinhibitory levels of caspofungin in the patient's peritoneal fluid and subsequently selection of the resistant mutant. Flucytosine-fluconazole cross-resistance due to nonsense and missense mutations in *FCY2* and *FCY1* genes is also observed for clinical isolates of *C. lusitaniae* (10). In the present case, isolates of *C. lusitaniae* with increased echinocandin MICs were recovered 2 weeks after initiation of caspofungin treatment, and these isolates exhibited missense mutation S645F in the HS1 region. Of note, among *C. albicans* isolates, amino acid changes at Ser 645 are more common and lead to the most significant MIC echinocandin increases (24). This is the first time that clinical isolates of *C. lusitaniae* with high echinocandin MICs due to mutation in hypothetical Fksp after caspofungin treatment are described. There is no available typing method for *C. lusitaniae*, which prevented analysis of the genetic relatedness between the 4 clinical isolates. However, this species is a rare human pathogen and its recovery from multiple anatomical sites and over time in the same patient makes it likely that the isolates are genetically linked. The recent demonstration that exposure to caspofungin influences the epidemiology of candidemia, the potential for *C. lusitaniae* to become an emerging pathogen in this setting (16), and the development of echinocandin resistance after caspofungin treatment should be taken into account for future therapeutic management.

We thank the Institut de Veille Sanitaire (InVS) for its financial support.

The technical help of Dorothée Raoux (NRCMA), of the Genotyping of Pathogens and Public Health platform, Institut Pasteur, and specifically of Anne-Sophie Delannoy, Laure Diancourt, and Jean-Michel Thiberge is gratefully acknowledged.

TABLE 2. Primers designed in this study to amplify hypothetical HS1 and HS2 regions of *Clavispora lusitaniae*

Primer name	Primer sequence, 5'-3'	Locus	Size of amplicon (bp)
MDO002	GCCTTTGGGTGGTTTGTTTA	HS1	696
MDO003	TCGGAATCTCTTGGGAAGAA	HS1	696
MDO004	TGCTGGTATGGGTGAACAGA	HS2	425
MDO005	CGAACACTTCGAAGAATGGAG	HS2	425

REFERENCES

1. Abruzzo, G. K., et al. 1997. Evaluation of the echinocandin antifungal MK-0991 (L-743,872): efficacies in mouse models of disseminated aspergillosis, candidiasis, and cryptococcosis. *Antimicrob. Agents Chemother.* **41**:2333-2338.
2. Baixench, M. T., et al. 2007. Acquired resistance to echinocandins in Can-

- dida albicans: case report and review. *J. Antimicrob. Chemother.* **59**:1076–1083.
3. Balashov, S. V., S. Park, and D. S. Perlin. 2006. Assessing resistance to the echinocandin antifungal drug caspofungin in *Candida albicans* by profiling mutations in FKS1. *Antimicrob. Agents Chemother.* **50**:2058–2063.
 4. Barnett, J. A., R. W. Payne, and D. Yarrow. 2000. *Yeasts: characteristics and identification*, 3rd ed. Cambridge University Press, Cambridge, United Kingdom.
 5. Bartizal, K., et al. 1997. In vitro preclinical evaluation studies with the echinocandin antifungal MK-0991 (L-743,872). *Antimicrob. Agents Chemother.* **41**:2326–2332.
 6. de Hoog, G. S., and A. H. Gerrits van den Ende. 1998. Molecular diagnostics of clinical strains of filamentous Basidiomycetes. *Mycoses* **41**:183–189.
 7. Desnos-Ollivier, M., et al. 2008. Mutations in the *fkp1* gene in *Candida albicans*, *C. tropicalis*, and *C. krusei* correlate with elevated caspofungin MICs uncovered in AM3 medium using the method of the European Committee on Antibiotic Susceptibility Testing. *Antimicrob. Agents Chemother.* **52**:3092–3098.
 8. Desnos-Ollivier, M., F. Dromer, and E. Dannaoui. 2008. Detection of caspofungin resistance in *Candida* spp. by Etest. *J. Clin. Microbiol.* **46**:2389–2392.
 9. Favel, A., et al. 2003. Colony morphology switching of *Candida lusitanae* and acquisition of multidrug resistance during treatment of a renal infection in a newborn: case report and review of the literature. *Diagn. Microbiol. Infect. Dis.* **47**:331–339.
 10. Florent, M., et al. 2009. Nonsense and missense mutations in *FCY2* and *FCY1* genes are responsible for flucytosine resistance and flucytosine-fluconazole cross-resistance in clinical isolates of *Candida lusitanae*. *Antimicrob. Agents Chemother.* **53**:2982–2990.
 11. Garcia-Effron, G., et al. 2010. Novel FKS mutations associated with echinocandin resistance in *Candida* species. *Antimicrob. Agents Chemother.* **54**:2225–2227.
 12. Holzschu, D. L., H. L. Presley, M. Miranda, and H. J. Phaff. 1979. Identification of *Candida lusitanae* as an opportunistic yeast in humans. *J. Clin. Microbiol.* **10**:202–205.
 13. Horn, D. L., et al. 2009. Epidemiology and outcomes of candidemia in 2019 patients: data from the prospective antifungal therapy alliance registry. *Clin. Infect. Dis.* **48**:1695–1703.
 14. Kahn, J. N., et al. 2007. Acquired echinocandin resistance in a *Candida krusei* isolate due to modification of glucan synthase. *Antimicrob. Agents Chemother.* **51**:1876–1878.
 15. Laverdiere, M., et al. 2006. Progressive loss of echinocandin activity following prolonged use for treatment of *Candida albicans* oesophagitis. *J. Antimicrob. Chemother.* **57**:705–708.
 16. Lortholary, O., et al. 2011. Recent exposure to caspofungin or fluconazole influences the epidemiology of candidemia: a prospective multicenter study involving 2441 patients. *Antimicrob. Agents Chemother.* **55**:532–538.
 17. Masclaux, F., E. Gueho, G. S. de Hoog, and R. Christen. 1995. Phylogenetic relationships of human-pathogenic *Cladosporium* (Xylohypha) species inferred from partial LS rRNA sequences. *J. Med. Vet. Mycol.* **33**:327–338.
 18. Odds, F. C., et al. 2007. One year prospective survey of *Candida* bloodstream infections in Scotland. *J. Med. Microbiol.* **56**:1066–1075.
 19. O'Donnell, K. 1993. *Fusarium* and its near relatives, p. 225–233. In D. R. Reynolds and J. W. Taylor (ed.), *The fungal holomorph: mitotic, meiotic and pleomorphic speciation in fungal systematics*. CAB International, Wallingford, United Kingdom.
 20. Park, S., et al. 2005. Specific substitutions in the echinocandin target Fks1p account for reduced susceptibility of rare laboratory and clinical *Candida* sp. isolates. *Antimicrob. Agents Chemother.* **49**:3264–3273.
 21. Perlin, D. S. 2007. Resistance to echinocandin-class antifungal drugs. *Drug Resist. Updat.* **10**:121–130.
 22. Pfaller, M. A., et al. 2010. Wild-type MIC distributions and epidemiological cutoff values for the echinocandins and *Candida* spp. *J. Clin. Microbiol.* **48**:52–56.
 23. Pfaller, M. A., and D. J. Diekema. 2007. Epidemiology of invasive candidiasis: a persistent public health problem. *Clin. Microbiol. Rev.* **20**:133–163.
 24. Pfaller, M. A., et al. 23 February 2011. Clinical breakpoints for the echinocandins and *Candida* revisited: integration of molecular, clinical, and microbiological data to arrive at species-specific interpretive criteria. *Drug Resist. Updat.* [Epub ahead of print.] doi:10.1016/j.drug.2011.01.004.
 25. Rodrigues de Miranda, L. 1979. *Clavispora*, a new yeast genus of the Saccharomycetales. *Antonie Van Leeuwenhoek* **45**:479–483.
 26. Snelders, E., et al. 2008. Emergence of azole resistance in *Aspergillus fumigatus* and spread of a single resistance mechanism. *PLoS Med.* **5**:e219.
 27. Subcommittee on Antifungal Susceptibility Testing (AFST) of the ESCMID European Committee for Antimicrobial Susceptibility Testing (EUCAST). 2008. EUCAST definitive document EDef 7.1: method for the determination of broth dilution MICs of antifungal agents for fermentative yeasts. *Clin. Microbiol. Infect.* **14**:398–405.
 28. Verweij, P. E., E. Snelders, G. H. Kema, E. Mellado, and W. J. Melchers. 2009. Azole resistance in *Aspergillus fumigatus*: a side-effect of environmental fungicide use? *Lancet Infect. Dis.* **9**:789–795.